ArticleNigerian medical journal : journal of the Nigeria Medical Association
The Analysis of Human Epidermal Growth Receptor-2 (HER-2) in Gastric Cancer in a Tertiary Hospital in Sub-Saharan Africa.
Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 0 citations in OpenAlex.
- Histopathological subtypes and topographical subsites of gastric cancer in Sub-Saharan Africa: a scoping review.BMC cancer · 2026Article
- Human epidermal growth factor receptor 2 expression and socio-demographic, clinical, and histopathological characteristics in gastric carcinoma at St Francis Hospital Nsambya, Uganda.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Ghana, gastric cancer contributes significantly to cancer morbidity and mortality. However, the recent usage of HER-2 monoclonal antibody in combination with chemotherapy has greatly improved the overall survival of patients. This study, therefore, aims at evaluating the pattern of HER-2 over expression in gastric carcinomas in Kumasi, Ghana. Methodology: Demographic data and histological diagnosis were retrieved from the surgical daybook of the Department of Pathology, Komfo Anokye Teaching Hospital, Kumasi. The slides were retrieved and reviewed to confirm the diagnosis, grading and classification of gastric cancer and immunohistochemistry was done with anti-HER-2 antibody to confirm HER-2 over-expression. Results: Of the 99 cases of gastric cancer seen over the 8 years, there were 57 males and 42 females. There were 91 adenocarcinomas, 5 GIST and 3 Non-Hodgkin Lymphoma. The age range of the study population was 8-90 years with a modal age group in the 6th decade. Of the adenocarcinomas, 45 were poorly differentiated, 38 moderately differentiated and 8 well differentiated. The diffuse type was most common with 47 cases followed by intestinal-type with 41cases and mixed type with 3 cases. Three of the 4 patients under the age of 30 years had lymphoma. HER-2 over expression was seen in 14 out of the 47 tested and all were intestinal type. Conclusion: HER -2 over-expression was seen in 30% of patients with gastric carcinoma especially those with intestinal-type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.